Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tacrolimus Monotherapy and Preemptive HCV Treatment in Liver Transplant Recipients
NCT00167557Phase 4Withdrawn
- Sponsor
- UTHealth Houston
- Start
- Jan 2005
- Primary completion
- Mar 2008
- Modality
- Recombinant Proteins and Enzymes, Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 4, open-label trial of pegylated interferon alpha and ribavirin in hepatitis C (HCV), sponsored by UTHealth Houston. Primary endpoint: Viral clearance after liver transplantation at 3 years. Planned start Jan 2005; status: withdrawn.
02
Drugs
pegylated interferon alpharibavirin
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT00167557.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00167557.